☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - October 2010

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Roflumilast (Daxas®) has been rejected as an add on to bronchodilator treatment in severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in 1 second post-bronchodilator <50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations. The manufacturer did not present a sufficiently robust economic analysis.

Four combined oral contraceptive pills (Rigevidon®, Gedarel®, Millinette® and TriRegol®) were all accepted for use in patients where these products would provide an appropriate form of contraception. They provide an alternative to the existing preparations at a lower cost.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - October 2010' by emailShare 'SMC Update - October 2010' on FacebookShare 'SMC Update - October 2010' on TwitterShare 'SMC Update - October 2010' on LinkedInShare 'SMC Update - October 2010' on reddit


No Comments to “SMC Update - October 2010”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.